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ABSTRACT
There is growing evidence for the accumulation of gadolinium (Gd) in patients administered with intravenous Gd-based
contrast agents, even in the absence of renal impairment. This review of the literature will discuss what has been found to
date in cadaveric human studies, clinical studies of patients and from animal models. Evidence for the potential route of
entry into the brain will be examined. The current state of knowledge of effects of Gd accumulation in the brain is
discussed. We will then discuss what the possible implications may be for the choice of Gd-based contrast agents in
clinical practice.
INTRODUCTION
Gadolinium (Gd)-based contrast agents (GBCAs) are
a cornerstone of radiological MRI with .300million pa-
tient administrations to date worldwide. Radiological
practices changed following the emergence of an associa-
tion between the administration of the less stable GBCAs in
patients with severe renal impairment and the very rare
condition nephrogenic system ﬁbrosis (NSF). GBCAs have
since been classiﬁed on the perceived risk of dissociation
and consequent risk for Gd to be released.1 However,
widespread use of GBCAs continues, including those most
frequently associated with NSF. Yet because of the response
of the radiology community, avoiding the less stable linear
chelate “high-risk” GBCAs in those patients known to be at
greatest risk with severe renal impairments, no new cases
related to exposure to the agents following the 2007 Food
and Drug Administration (FDA) warning have been
reported. There have been cases of NSF manifesting sub-
sequent to the FDA warning that have been reported, but
all associated with the administration of high-risk GBCAs
in severe renal impairment prior to the FDA warning in
2007, essentially late presentations, although the reasons
for these delays are obscure.2,3 All diagnostic radiological
practice involves a balancing of the estimated risk of an
investigation vs the perceived beneﬁts of the information
to be gained from it. Recently, there have been a series
of publications investigating signal hyperintensity on
unenhanced T1 weighted (T1w) MRI of the brain (in-
volving the dentate nucleus and basal ganglia) in patients
who have previously been administered multiple doses of
GBCAs, which indicates that Gd may deposit long term in
the brain. Have the scales just been tilted again?
GBCAs are used for contrast enhancement of MRI and for
MR angiography because of the paramagnetic properties of
the Gd ion with 7 unpaired electrons. Free Gd ions are
known to be highly toxic hence their formulation as
a chelated compound for intravenous administration.
Gd31 ions are the same diameter as Ca21 and are capable
of binding to many of the same sites as calcium.4 GBCAs
are made safe for clinical use by binding the ions to a li-
gand. The ligand binds tightly to the Gd ion permitting the
excretion of the intact complex. GBCAs have the potential
for dissociation of Gd from the chelate, releasing Gd ions
into the patient although the formulation of the chelate is
designed to absolutely minimize this. The chemical prop-
erties of the ligand molecule determine how likely this is,
and the process is inﬂuenced by the environment of the
molecule. For the GBCAs authorized in the EU, the most
stable ones with the lowest potential for dechelation
(conditional stability being the measure that matters in this
respect) are the macrocyclic GBCAs. Data from both ani-
mals and humans have so far demonstrated that Gd can
accumulate in a range of tissues and organs, including the
skin, bone, liver, kidney, muscle and spleen albeit in very low
concentrations. However, the exact state of this Gd in terms of
whether it has been dechelated and bound now to another
compound or still as the intact original GBCA is not always
clear, although it appears that dechelation does occur at least to
some extent with the less stable high-risk linear chelates; this has
not been shown with any of the macrocyclic GBCAs.5,6 Table 1
lists the GBCAs available in the EU, their product name, the
relevant generic name, risk category and structure.
Deposition of Gd in patients with severe renal impairment is
associated with NSF, a condition ﬁrst described in 2000, al-
though the link to GBCA use for imaging was not made until
2006.7–11 NSF is a serious, sometimes life-threatening, condition
involving ﬁbrosis, notably of the skin, and where this is across
joints, mobility is reduced. In more severe cases, there is ﬁbrosis
of the internal organs such as the liver, lungs and heart with
potential consequent morbidity and mortality. Prolonged elim-
ination times in patients with severe renal impairment and re-
lease of Gd from ligand molecules are the main factors thought
to be associated with the development of NSF, although other
factors must inﬂuence this since only a small proportion of renal
failure patients exposed to high-dose, high-risk GBCAs develop
NSF.11 This release of Gd is dependent on the chemical envi-
ronment, so called conditional stability, which is pH dependent:
acidic conditions promoting release.12 Port et al12 demonstrated
greater conditional stability amongst macrocyclic GBCAs and
with ionic rather than non-ionic GBCAs. There is no data on the
effect of varying causes of metabolic acidosis on stability of
GBCAs in vivo, although acidosis seen in renal failure is viewed
as a contributor to the risk created by administering high-risk
linear chelate GBCAs to patients with renal impairment. The
clinical signiﬁcance of other metabolic acidoses as potential
promoters of dechelation of GBCAs is uncertain. The clinical
signiﬁcance of other situations associated with local drops in pH
is also unclear. The pH of muscles may drop during exercise.
The pH in pus can be very low, but furthermore, it is not known
if free oxygen radicals created during the response to infection
clinically affect the stability of GBCAs? Similarly, the pH in some
tumours can be lower than normal tissue. Yet GBCAs, when not
being used for MR angiography, are generally given to demon-
strate or exclude enhancement from inﬂammation or tumours.
The mechanism by which Gd may accumulate in brain tissue
is not known for certain although it has been demonstrated
to cross the blood–cerebrospinal ﬂuid (CSF) barrier, and it is
not certain in what state this occurs and is accumulated.
Maramattom et al13 reported a case where a 57-year-old female
with end-stage renal failure developed a reduced, ﬂuctuating
level of consciousness and mild left-sided weakness after repeated
contrast-enhanced scans, and the exact dose was uncertain (but
thought to be 60–80ml) and, unfortunately, the speciﬁc Gd
chelate used was not ascertained. Gd-related signal change was
present in the CSF on MRI scan, and there was resolution after
dialysis. Hui and Mullins14 reported a similar case of a patient
who underwent MRI and MR angiography with apparent CSF
accumulation of contrast which was associated with encepha-
lopathy but which resolved with dialysis, and although not
speciﬁcally stated, the report suggests this patient also was in
end-stage renal failure; again, the authors do not specify the
particular contrast agent used or the dose employed. More
recently, accumulation of perivascular spaces in the CSF has
been reported in context of delayed post GBCA-enhanced MRI
for endolymphatic hydrops in people with presumably normal
renal function.15 It has been postulated that once across the
blood–CSF barrier, the GBCA would then enter the lymphatic
system.15 Whether this explains the preferential distribution
with the dentate nucleus and globus pallidus is not clear.
The location relative to the blood–brain barrier (BBB) of the Gd
may be important in determining the future risks to the patient.
Is the deleterious effect, if any, of Gd to the brain tissue de-
pendent on crossing the BBB in order to be toxic to the neurons
or glia? Gd could potentially cross the BBB either because it is
locally or diffusely permeable to the intact GBCA or of passage
of the dechelated Gd, with or without the use of a transport
Table 1. Summary of gadolinium-based contrast agents available in the market
Product name Generic name EMEA NSF risk category Structure
Magnevist (Bayer) Gadopentetate dimeglumine High Linear ionic
Omniscan (GE HealthCare) Gadodiamide High Linear non-ionic
Optimark (Mallinkrodt) Gadoversetamide High Linear non-ionic
MultiHancea (Bracco) Gadobenate dimeglumine Medium Linear ionic
Primovista (Bayer) Gadoxetic acid Medium Linear ionic
Ablavara Gadofosveset trisodium Medium Linear ionic
Dotarem (Guerbert) Gadoteric acid Low Macrocyclic ionic
Gadovist (Bayer) Gadobutrol Low Macrocyclic non-ionic
ProHance (Bracco) Gadoteridol Low Macrocyclic non-ionic
EMEA, European Agency for the Evaluation of Medicinal Products; NSF, nephrogenic systemic fibrosis.
The data in the table are categorized by product name (by NSF risk category and alphabetical order of product name within category), active
substance, NSF risk category and structure of chelating agent.
aThese agents are categorized as medium risk even though they have not been linked unconfounded to any NSF cases, perhaps because of their dual
hepatic and renal excretion and relatively higher stability constants than the other linear agents.
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system. Common indications for the use of GBCAs are to
demonstrate manifestations of the breakdown of the BBB, for
example, in brain tumours and inﬂammation of the brain such
as in infection or autoimmune disease. In these circumstances,
the GBCA agent itself could accumulate in brain tissue without
any chemical change. Equally, it could also represent a potential
route for egress of the agent from brain tissue. In addition,
workers such as Wardlaw et al,16 Topakian et al17 and Taheri
et al18 have suggested that GBCAs may cross the BBB in the
context of endothelial dysfunction and small vessel disease.
Wardlaw et al,19 for example, assessed patients within a month
after lacunar or cortical stroke. They found diffused increases in
T1 signal within the CSF, 30min after the intravenous admin-
istration of gadodiamide. Given the population prevalence of
small vessel disease and stroke, it suggests that the size of the
population at risk of accumulating Gd by this potential mech-
anism is relatively large.
In their systematic review from 2014 of assessment of BBB
disruption using contrast-enhanced MRI, the Wardlaw group
identiﬁed 70 studies of which 45 had used gadopentetate
dimeglumine, 15 had used gadodiamide, with 10 studies using
a range of other agents including gadoterate meglumine, gado-
butrol and gadoteriol.20 There were no studies that presented
comparison between these agents although the apparent dem-
onstration of permeability of the BBB is clearly not limited to
gadodiamide and gadopentetic acid. These studies also have
implications for design of animal studies which need to reﬂect
the clinical reality of the patients exposed to GBCAs, as has
already been highlighted by Pietsch et al.21,22 Alternatively, it is
possible that if Gd accumulates in brain tissue, it does so after
release from a reservoir such as bone given that there is evidence
for Gd being present in small amounts in the skin and bone after
exposure to GBCAs, including macrocyclic agents, even when
renal function is normal.23 This means that there is a potential
for effects long after Gd exposure, for example, Thomson et al
reported the development of NSF in a patient for more than
6 years following gadodiamide exposure, whereas Larson et al24
reported NSF 10 years after Gd3 exposure—the speciﬁc GBCA
used was not stated in this report but highly likely to have been
a high-risk GBCA given the period and geographical location in
question. Thomson et al3 have also reported delayed pre-
sentations of NSF from prior exposure to high-risk agents. The
implications, if any, of long-term bone deposition for in utero
exposure and breast feeding are unclear.
So why should Gd apparently particularly deposit in relation to
the basal ganglia and dentate nuclei rather than at other sites in
the brain? The dentate nucleus, particularly, is a depository for
copper and zinc which are required for normal function, and
these are known to chelate with diethylenetriaminepentaacetic
acid.25 Furthermore, it is known that transmetallation occurs
with chronic exposure to both manganese and lanthanum (the
latter, of course, a lanthanide of the same series as Gd in the
periodic table) with subsequent neurotoxicity, therefore perhaps
this is a similar process.26–28
Alternatively, as discussed above, the Gd31 ion is the same di-
ameter as a Ca21 ion and is known to substitute for it in
metabolic processes.4,29,30 In this regard, it is interesting that the
sites that Gd seems to accumulate in the brain are those that are
most likely to calcify normally, the globus pallidus and the deep
cerebellar nuclei (DCN) which includes the dentate nucleus.
This naturally raises questions about what might inﬂuence such
uptake into brain tissue. Are those conditions that promote
calciﬁcation in the brain, such as hypoparathyroidism amongst
many others, risk factors for increased Gd uptake? Birka et al31
published evidence from a patient with proven NSF that Gd was
codistributed with phosphorus in the skin and in vessel walls.
Does the existing calcium (or associated phosphate) concen-
tration in brain tissue affect deposition, and this might therefore
suggest an increasing risk with ageing in those regions prone to
calciﬁcation with normal ageing?
What is the actual evidence for Gd accumulation in the brain?
There are essentially 4 areas of evidence which may be con-
sidered in a hierarchical way. Firstly, there are cadaveric studies
where mass spectrometry has been used to measure Gd con-
centrations in human brain tissue from the cadavers of patients
with documented histories of GBCA exposure in the past.
Secondly, there have been human tissue studies which have
demonstrated the presence of Gd with mass spectrometry in
brain tissue obtained from patients with brain tumours at the
time of neurosurgery and with recent exposure to GBCAs.
Thirdly, there are non-clinical studies in animal models used to
test hypotheses arising from the above studies and from the
fourth group, clinical observational studies in speciﬁc patient
populations.
CADAVERIC STUDIES
There are 2 cadaveric studies published which collectively report
the results of analysis of pathological specimens from 18 post-
mortem cases with good histories detailing GBCA exposure.
McDonald et al32 compared brain tissue at post-mortem ex-
amination from 13 patients exposed to gadodiamide (Omnis-
can) for brain MRI and with known contrast administration
histories. All of the patients had had normal renal function at
the time of GBCA exposures. The exposed group had received
4 or more administrations (up to 29) of gadodiamide between
2000 and 2014. All of the 13 patients exposed to gadodiamide
for brain MRI had detectable Gd in brain tissue from the dentate
nucleus, pons, globus pallidus and thalamus (0.3–58.8mg per
gram of tissue). Samples from 10 control patients who had not
received GBCAs did not contain detectable levels of Gd.
Changes in pre-contrast T1 signal on MRI in the dentate nu-
cleus strongly correlated with the amount of tissue Gd assayed
with mass spectrometry (r5 0.93, p5 0.0001). McDonald
et al32 also investigated the localization of Gd within neuronal
tissues and assessed for histological changes using transmission
electron microscopy. They found that among Gd-exposed
samples, Gd was prominently clustered in large foci within the
endothelial wall with apparently only a small proportion hav-
ing crossed the BBB into the neuronal interstitium itself. They
also stated that “Despite direct evidence of Gd deposition
within neuronal tissues, we were unable to detect gross histo-
logical changes between contrast and control groups in
hematoxylin–eosin–stained tissues samples with visual light
microscopy”.
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Kanda et al33 have also reported that Gd was detected in post-
mortem brain tissue samples by mass spectrometry in ﬁve
patients who had all been exposed to multiple doses of linear
chelate GBCAs. Samples from ﬁve control patients who did not
receive GBCAs contained levels of Gd that were many fold
lower/undetectable. The exposed group had received at least two
doses of linear chelate GBCAs, and most of these were of
gadopentetate dimeglumine. One patient had an additional ex-
posure to gadodiamide and another patient had additional
exposures to gadodiamide and gadoteridol. None of the subjects
had abnormal renal function at the time of the GBCA admin-
istrations. Kanda et al33 also demonstrated that after intravenous
infusion, Gd accumulates in the brain, ﬁnding a mean con-
centration of 0.25mg per gram of brain tissue 60.44 (standard
deviation). This is in good agreement with the evidence from
McDonald et al.32 The concentration of Gd was higher in the
dentate nucleus and globus pallidus (mean, 0.44mg g21 60.63)
than in other brain regions (mean, 0.12mg g21 60.16)
(p5 0.029). However, the high-risk linear GBCAs gadopentetate
dimeglumine and gadodiamide were the predominantly ad-
ministered agents, and while the cyclic chelate gadoteridol was
also used, in none of the patients was this agent used un-
confounded with the linear agents, plus in these two patients,
the measured Gd concentrations were lower than the mean.
Of particular note in both these cadaveric studies is that the
levels of Gd detected are orders of magnitude lower than would
be expected to give rise to visible signal on routine T1w brain
MRI sequences. Therefore, even if low levels of Gd have been
deposited in some form, why is hyperintensity visible on T1w
brain imaging?
HUMAN TISSUE STUDIES
Xia et al34 published a study of brain tumour biopsy samples
evaluated using scanning electron microscopy/energy dispersive
X-ray spectroscopy, which is a different technique to the ca-
daveric studies of McDonald et al32 and Kanda et al.33 The
technique used by Xia et al34 enables some spatial localization at
the level of the scanned electron micrograph. The cadaveric
studies used inductively coupled plasma mass spectrometry
which has much higher sensitivity, several orders of magnitude
greater, although it lacks the spatial localization as the tissue is
converted to plasma for analysis. The brain tissue samples
analysed by Xia et al34 were from patients undergoing tumour
resection who had received at least one MRI with gadodiamide.
Some of the patients had further MRI scans with gadobenate
dimeglumine, although again, none with this agent alone un-
confounded with the high-risk gadodiamide. The brain tissue
samples were taken at surgery performed soon after the last
scan, median 1 day (range 0–9 days). Insoluble Gd was found
deposited in association with phosphorus and calcium in seven
specimens from ﬁve patients. These deposits were primarily in
highly vascular areas, for example, frequently within the walls of
blood vessels which given their location in a brain tumour are
likely to have an abnormal BBB. The deposits were also found in
association with calciﬁcation. Gd deposits were more common
in biopsies from patients with more than one MRI scan. Of the
biopsies included in the analysis, 31% (4/13) of those with more
than one GBCA-enhanced MRI scan had deposits, whereas only
6.6% (1/15) of those with only one MRI scan had Gd deposits.
This suggests longer term accumulation from prior scans as
indicated by the cadaveric studies and not just a temporary
phenomenon.
NON-CLINICAL ANIMAL MODEL STUDIES
Robert et al35 reported T1 signal hyperintensity in the DCN after
administration of gadodiamide to healthy rats with normal renal
function (n5 7). The rats were given 20 intravenous injections
of 0.6 mmol of Gd per kilogram (4 injections per week during
5 weeks) of one of gadodiamide, gadoteric acid or saline (control
group). However, it should be noted that this is very much
higher and more frequent doses than would be given in normal
clinical practice. T1w MRI of the brain was performed using
a 2.35-T system before and once a week during the 5 weeks of
injections and during 5 additional weeks (treatment-free period)
to detect either persistence or any washout effects. Gd concen-
trations were measured with inductively coupled plasma mass
spectrometry in plasma and brain (the same technique as in the
cadaveric studies discussed earlier). A signiﬁcant and persistent
T1 signal hyperintensity in DCN including the dentate nucleus
was observed only in gadodiamide-treated rats. The T1 signal
increases detected persisted to the end of the 5-week treatment-
free period. No quantiﬁable Gd was found in the plasma of rats
at completion of the treatment-free period (i.e. 5 weeks after the
last administration). The total Gd concentration was signiﬁ-
cantly higher (in the cerebral cortex, subcortical brain and cer-
ebellum) in gadodiamide-treated rat than in gadoterate-treated
rats. This study conﬁrms that not all of the GBCAs behave the
same with respect to brain accumulation and conﬁrms the
change in T1 signal that has been reported in observational
clinical studies. Jost et al36 studied Wistar-Han rats dosed with
either gadodiamide, gadopentetate dimeglumine, gadobenate
dimeglumine, gadobutrol, gadoterate meglumin or saline as
a control with the GBCAs administered in 25-fold doses com-
pared with human clinical use. Rat brain imaging was performed
at 1.5 T and showed signal hyperintensity after administration of
the linear agents but not the macrocyclics or saline control. The
gadodiamde-dosed animals also showed NSF-like skin changes,
whereas none of the others did. Histology of the rat-brain deep
nuclei showed no adverse histology in any of the subjects. Very
low concentrations of Gd were found in the brain tissue 15-fold
higher for the linear agents with levels in those administered
macrocyclics extremely low. An extremely interesting ﬁnding
from this work is that using chromatography of aqueous cere-
bellar homogenates, there was a peak indicating Gd bound to
macromolecules in the 200–300 kD from the brains of rats ad-
ministered with gadodiamide that was not seen with those ad-
ministered with macrocyclic agents. This is strong evidence that
for the gadodiamide-dosed rats, there has been dechelation with
transmetallation of Gd to macromolecules and this could well
explain the T1w signal hyperintensity at low Gd concentrations,
as these macromolecules would be slowly rotating complexes
with particular conspicuity at 1.5 T. What these macromolecules
could be is of course uncertain at this time, but one suggestion
has been that it could be neuromelanin.
If the GBCA manufacturers are in possession of other similar
unpublished data covering the full range of marketed GBCAs in
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clinical use, it should be incumbent upon them to make this
publicly available in the view of the authors.
Kartamihardja et al37 assessed Gd deposition in the brain of mice
after multiple (20) injections of gadodiamide (Gd-DPT-BMA),
gadoteric acid (Gd-DOTA), both at 5mmol kg21 or gadolinium
(III) chloride at 0.02mmol kg21. These are much higher doses
than used clinically. In contrast to Robert et al,35 when using
T1w imaging performed at 1.5 T to visualize the deposition in
the brain approximately 1 week after the 20th injection, no
difference in the contrast-to-noise ratio could be determined.
However, tissue Gd concentrations detected using inductively
coupled plasma mass spectrometry showed gadodiamide was
associated with the highest deposition in the brain and the skin
compared with a macrocyclic GBCA comparator, gadoteric acid.
No clinical effects or increases in skin thickness were identiﬁed
associated with this study. This study also indicates differential
rates of accumulation in the brain depending on the chemistry
of the GBCA administered and that this may arise in the pres-
ence of normal renal function.
CLINICAL OBSERVATIONAL STUDIES
There are 11 separate clinical observational studies which report
the ﬁndings from 681 patients in total including a study focusing
on children.38–48 All of the patients reported in these studies had
normal renal function at the time of the administration of the
GBCAs. The methodology employed to observe the effects of the
presence of Gd in all these studies has been to measure changes
of T1 signal (not T1 mapping) relative to a “control” area such
pons, a peduncle or other white matter area. If the concentration
of Gd in the brain reﬂects that seen in the cadveric studies, it is
surprising that there was a measurable T1 signal effect at all if it
is a directly attributable phenomenon. However, more recent
studies have now used T1 and T2 mapping to conﬁrm the earlier
studies reporting T1 signal change.
47,48 The most likely emerging
explanation for this comes from the pre-clinical work of
Pietsch’s group discussed above who have noted the following.49
Firstly, T1 signal hyperintensity is most prominent at 1.5 T im-
aging and less conspicuous if visible at all at higher ﬁeld
strengths. Secondly, in aqueous cerebellar homogenates from the
brains of rats administered with gadodiamide, there is a chro-
matographic peak at 200–300 kD indicating Gd is bound to
a macromolecule, a phenomenon not seen with the macrocyclic
agents. Gd bound to such a macromolecule could well give rise
to signal at 1.5 T even at low concentrations since it would
exhibit slower tumbling, a mechanism akin to the increased
relaxivity where agents such as gadofosveset bind to albumin
in plasma. This effect rapidly reduces at ﬁeld strengths higher
than 1.5 T. This is strong secondary evidence that the Gd
found in these deep nuclei are indeed due to Gd ions deche-
lated from the ligand caldiamide that is formulated in gado-
diamide, an agent with much lower conditional stability
compared with macrocyclic agents. Alternatively, the signal
change may represent secondary changes such as alterations in
iron or calcium concentration or even other elements such as
manganese locally in those areas of Gd accumulation. Greater
knowledge about the location and state of the Gd in tissue
could be useful for identifying both the possible biological
effects on the brain and the possible reversibility of the
accumulation. Interestingly in mice, there appears to be very
different rates of clearance of gadopentetate dimeglumine
from different brain structures after a single bolus.50 CSF and
the subdural space are quickly cleared, but there is detectable
gadopentetate dimeglumine for many hours in the cortex and
subcortical grey matter.50
The indications varied for the administration of GBCAs between
the different study populations across the studies. The main
indication for an MRI scan with a GBCA was investigation for
brain tumours, but some were for stroke and others multiple
sclerosis. However, all of these groups of patients would be
potentially expected to not have a fully functional BBB. Thus, it
is possible that Gd accumulated in the brain at the time of the
injection rather than redistribution from another site of se-
questration. The majority of the studies reported ﬁndings from
patients with a history of multiple exposures, most reporting ﬁve
or more separate administrations. All studies report changes of
T1 signal in dentate nucleus and/or globus pallidus. In general,
the studies show increase in T1 signal proportional to increasing
exposure. Increases in T1 signal in the dentate nucleus and the
globus pallidus have been frequently linked to gadodiamide and
to gadopentetic acid exposure. One study shows decrease in T1
signal after gadobenic acid.40 Stojanov et al44 demonstrated
a change in T1 signal in the dentate nucleus and the globus
pallidus in a group of 58 patients with multiple sclerosis that had
gadobutrol administered on average 4.74 times. The authors of
this study hence suggest that the accumulation in the brain is not
limited to linear chelated GBCAs. However, this study can be
criticized on several counts, not least that there is no control for
potential prior confounding agent administration, the correla-
tion of 0.263 is very weak and there is no visible signal hyper-
intensity on any of the imaging supplied in the article.51 Indeed,
Radbruch et al45 failed to demonstrate any T1 signal change in
the same brain regions of patients with repeated exposure to
gadoteric acid. Thus, the evidence regarding the macrocyclic
agents causing T1 signal hyperintensity is currently far less
strong than for the linear agents gadodiamide and gado-
pentetic acid.
The clinical evidence that Gd accumulation in whatever form is
deleterious to the brain is surprisingly limited. Arlt et al52
reported a case of toxicity following accidental intrathecal in-
jection of the linear chelate gadopentetic acid. Short-term
problems largely resolved, but the patient was left with “very
mild” gait ataxia. Clearly, this case is potentially consistent with
Gd accumulating in the dentate nucleus of the cerebellum, but
there was no relevant imaging performed. The Maramattom
et al13 case report discussed previously indicated the Gd accu-
mulation was associated with a ﬂuctuating level of consciousness
and mild left-sided weakness with resolution after dialysis. The
patient in the report by Hui and Mullins14 with apparent CSF
accumulation of contrast also had encephalopathy which re-
solved with dialysis. There are also non-clinical studies that
support linear chelate Gd-based contrast agent neurotoxicity
when they are injected directly into the CNS.53,54 However to
date, in none of the studies where T1 hyperintensity has been
shown in the brain on imaging have any deleterious clinical
effects been observed.
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DISCUSSION
The studies reviewed present different lines of evidence that
suggest that Gd may accumulate in brain tissue after intravenous
administration of GBCAs in humans even in the absence of
renal impairment although at very low concentrations (23 times
lower than in the bone).21 The amounts are signiﬁcantly higher
for the less stable linear chelate GBCAs that have been associated
with the development of the rare disorder of NSF in patients
with severe renal impairments. Only in patients exposed to
multiple doses of these less-stable linear chelate GBCAs have
visible signal changes been manifest in the brain (dentate nu-
cleus and globus pallidus) on T1w MRI scans. In these patients,
the Gd concentrations are lower than should give signal if still
chelated as originally formulated, suggesting dechelation and
transmetallation with the Gd ion passing to a macromolecule.
Which clinical circumstances are clinically signiﬁcant in pro-
moting dissociation of Gd from its chelator and accumulation in
the brain in the absence of renal failure, if any, represents
a signiﬁcant knowledge gap.
However, what is also absent at present is evidence for a clinical
effect of the presence of Gd in the brain and in the dentate
nucleus and globus pallidus in particular. Even in animal
models, evidence for a toxic effect of Gd accumulation in rat
brain tissue from multiple intravenous injections of both linear
and macrocyclic contrast agents is currently lacking.55 In no
patient in whom T1w signal hyperintensity has been observed
has there been associated clinical neurological sequelae. Where
are the patients presenting with ataxia and movement disorders?
Equally, how many patients worldwide were administered
GBCAs before NSF was recognized? Are neurologists enquiring
about exposure to GBCAs amongst their patients with idiopathic
sporadic ataxia or with other movement disorders? Clearly, the
fact that many of the patients administered multiple doses of
GBCAs will have had such for the investigation of neurological
conditions is a confounding factor for evaluation of any new
subtle neurological problem.
Therefore, although there is growing evidence tilting the
scales away from routine use of GBCAs further than pre-
viously if a precautionary approach is adopted, there is an
important knowledge gap on the signiﬁcance of Gd accu-
mulation in the brain which needs to be addressed as a matter
of urgency. There is clear evidence that the accumulation of
Gd happens and that it varies depending on the agent in
question. Furthermore, the accumulation is likely in different
forms (dechelated and subsequently bound to macromolecules
vs remaining tightly bound in original GBCA form), again
dependent upon the class of agent in question. This will have
important implications in terms of putative toxicity. This evidence
for or against toxic effects needs to be strengthened, but the
clinical community and health institutions have a duty of care. A
circumspect approach is to limit or even avoid the use of GBCAs
where possible. But given that the clinical signiﬁcance of the
indications for the radiological use of GBCA, the clinical need for
a safe GBCA will remain. Indeed their clinical utilization is likely
to remain widespread for the foreseeable future. In the UK, choice
of GBCAs tends to be taken at an institutional level. This duty of
care suggests that choice of GBCAs institutionally available cannot
be entirely cost driven and that unless the distinct properties of
a particular linear agent are speciﬁcally required (e.g. for liver or
vascular imaging), then the preference should be for a “low-risk”
macrocyclic agent.
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